Selectis Health (OTCMKTS:GBCS – Get Free Report) and Progyny (NASDAQ:PGNY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
94.9% of Progyny shares are held by institutional investors. 15.2% of Selectis Health shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Selectis Health and Progyny, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Selectis Health | 0 | 0 | 0 | 0 | 0.00 |
| Progyny | 0 | 4 | 9 | 0 | 2.69 |
Profitability
This table compares Selectis Health and Progyny’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Selectis Health | -2.45% | N/A | -3.03% |
| Progyny | 4.54% | 11.37% | 7.73% |
Valuation & Earnings
This table compares Selectis Health and Progyny”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Selectis Health | $41.44 million | 0.34 | -$1.02 million | ($0.34) | -13.46 |
| Progyny | $1.29 billion | 1.13 | $58.52 million | $0.65 | 28.62 |
Progyny has higher revenue and earnings than Selectis Health. Selectis Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Selectis Health has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500. Comparatively, Progyny has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.
Summary
Progyny beats Selectis Health on 13 of the 14 factors compared between the two stocks.
About Selectis Health
Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.
About Progyny
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Receive News & Ratings for Selectis Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selectis Health and related companies with MarketBeat.com's FREE daily email newsletter.
